Next Article in Journal
Independent Predictors of Mortality in Torso Trauma Injuries
Next Article in Special Issue
Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure
Previous Article in Journal
The Quality of Life and Psychosocial Implications of Cancer-Related Lower-Extremity Lymphedema: A Systematic Review of the Literature
Previous Article in Special Issue
Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
Open AccessArticle

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

1
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
2
Department of Clinical Biochemistry, “Aghia Sophia” Children’s Hospital, 11527 Athens, Greece
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(10), 3201; https://doi.org/10.3390/jcm9103201
Received: 8 September 2020 / Revised: 26 September 2020 / Accepted: 2 October 2020 / Published: 3 October 2020
(This article belongs to the Special Issue New Therapies and Therapeutic Approaches in Multiple Myeloma)
(1) Background: Soluble urokinase-type plasminogen activator receptor (suPAR) has been implicated in the pathogenesis of kidney disease in different disease settings. The aim of this study was to investigate a possible link between suPAR circulating levels and renal impairment (RI) in newly diagnosed patients with symptomatic multiple myeloma (NDMM) before and after frontline therapy with bortezomib-based regimens. (2) Methods: We studied 47 NDMM patients (57% males, median age 69.5 years) before the administration of anti-myeloma treatment and at best response to bortezomib-based therapy. suPAR was measured in the serum of all patients and of 24 healthy matched controls, using an immuno-enzymatic assay (ViroGates, Denmark). (3) Results: suPAR levels were elevated in NDMM patients at diagnosis compared to healthy individuals (p < 0.001). suPAR levels strongly correlated with disease stage (p-ANOVA < 0.001). suPAR levels both at diagnosis and at best response negatively correlated with estimated glomerular filtration rate (eGFR) values (p < 0.001). Interestingly, no significance changes in suPAR levels were observed at best response compared to baseline values (p = 0.31) among 18 responding patients with baseline eGFR < 50 mL/min/1.73 m2. (4) Conclusions: SuPAR levels reflect renal function in NDMM patients treated with bortezomib-based induction. Responders may have elevated circulating suPAR levels, possibly reflecting persistent kidney damage, despite their renal response. View Full-Text
Keywords: suPAR; soluble urokinase-type plasminogen activator receptor; multiple myeloma; bortezomib; induction; kidney; renal suPAR; soluble urokinase-type plasminogen activator receptor; multiple myeloma; bortezomib; induction; kidney; renal
Show Figures

Figure 1

MDPI and ACS Style

Terpos, E.; Ntanasis-Stathopoulos, I.; Papassotiriou, G.-P.; Kastritis, E.; Margeli, A.; Kanellias, N.; Eleutherakis-Papaiakovou, E.; Migkou, M.; Fotiou, D.; Roussou, M.; Gavriatopoulou, M.; Malandrakis, P.; Psimenou, E.; Papassotiriou, I.; Dimopoulos, M.A. Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. J. Clin. Med. 2020, 9, 3201.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop